ARS turns fifteen: la quinceañera bonita.
ARS was aimed at advancing the erstwhile niche field of redox biology to a more central position in research. Currently, ARS ranks first (impact factor: 8.456) in the field of redox biology. Of 8336 journals listed in Journal Citation Reports, ARS ranks 205th. The next journal in redox biology ranks 449th. ARS ranks 169th of 8336 in immediacy index. The next journal in redox biology ranks 923rd. Thus, ARS is the primary source of hot papers in redox sciences and healthcare. To grow footprint and overall impact, ARS has nearly doubled the annual publication volume from roughly 200 to 400 in one year. Because the manuscript volume represents the denominator of the impact factor calculation, such a sharp increase in volume would be predicted to a proportionally lower impact factor. Because of the robust current upward momentum, ARS will be affected less than that predicted by simple arithmetic and will maintain its top position even after such aggressive volume expansion. As another year passes, the additional manuscripts will get more time to be cited, and therefore the impact factor is expected to bounce back resulting in a much stronger journal with a substantially enhanced overall presence. ARS currently publishes 36 issues annually as two series: ARS-Discoveries, and ARS-Therapeutics. Redox biology does have the potential of major health impact. ARS-Therapeutics is the first and only forum dedicated to highlight that strength. I am grateful to the global redox village for their unreserved support to raise ARS and this fascinating field of redox research and healthcare. Antioxid. Redox Signal. 18, 1-4.